An interventional study of Proactive Risk-Based Optimization and Notifications for Treatment and Outcomes (PRONTO) in Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Head &Amp;Amp; Neck Squamous Cell Carcinoma and Larynx Squamous Cell Carcinoma, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Mouth Neoplasms with a site in Canada — 7 open to participants now, 9 under way, 1 of them phase 3. Mouth Neoplasms · Canada.
Among the 23 studies in Mouth Neoplasms with a site in Canada, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 with no phase, and was the 22nd registered.
447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.
Browse Mouth Neoplasms studies →7 of the 23 studies in Mouth Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18–65
University of British Columbia · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 18+
National Cancer Institute (NCI) · Sites in Canada, United States
Ages 18+
NRG Oncology · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 5 · Phase 4 1
First in 1999; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 85 is above the median of 60 across 313 interventional studies indexed under Mouth Neoplasms.
Median enrollment 40 across the 18 interventional studies, 500 across the 3 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 23 have an industry lead sponsor. The 10 most frequent:
Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Centre hospitalier de l'Université de Montréal (CHUM) has 2 studies filed under Mouth Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Mouth Neoplasms with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05172245National Cancer Institute (NCI)Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | 2027-07-01 |
| NCT05429099University of British ColumbiaMandibular Reconstruction Preplanning (ViPMR) | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Mouth Neoplasms with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Delays between surgery and the initiation of post-operative radiotherapy (S-PORT) in head and neck cancer (HNC) patients are prevalent and associated with worse oncologic outcomes. This pilot study evaluates whether a proactive, automated care coordination system (PRONTO-HN) can improve adherence to recommended S-PORT intervals of ≤42 days at the Centre hospitalier de l'Université de Montréal (CHUM).
The study is a single-center, quasi-experimental, interrupted time-series design with two phases. Group A (control) includes patients treated before the intervention (using a prospectively maintained database from August 2024 to August 2025). Group B (intervention) includes patients treated with the new coordination system from September 2025 to September 2026.
The intervention includes automated alerts, multidisciplinary task coordination, and risk stratification based on a predictive model developed and published by our team. This model uses only pre-operative data to estimate the likelihood that a patient will require adjuvant therapy after surgery, stratifying patients into high- and low-risk categories. High-risk patients receive intensified coordination protocols, including early oncology and dental consultations and shorter target times for pathology results.
Primary objective: Reduce the proportion of patients with S-PORT > 42 days. Secondary/tertiary objectives: Reduce mean S-PORT time. Evaluate impacts on overall, locoregional, and disease-free survival in a 2- and 3-year follow up study.
Patients are identified at the time the operating room request is submitted. Demographic, clinical, and oncologic data are collected and stored securely in REDCap. As the intervention is administrative in nature and does not modify patient care, consent is waived.
Statistical analysis will evaluate the intervention's effect and identify predictors of delays. A sample of 38 patients per group provides adequate power to detect a drop in S-PORT > 42 days from 80% to 50%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pre-implementation of care coordination system.
Post-implementation of PRONTO-HN system: 1. Pre-operative risk stratification of requiring adjuvant therapy using our predictive model, applied at tumor board. Patients stratified as fast-track vs normal-track. 2. High-risk patients receive intensive preoperative and postoperative coordination. Low-risk patients are monitored but escalated rapidly if adverse pathology is detected. This includes: * pre-operative dental consultation for fast-track * pre-operative oncology consultation for fast-track with high-risk features * target pathology results 14 days post-operatively for fast-track 3. Automated reminders and target dates sent to members of the multidisciplinary team.
Other: Proactive Risk-Based Optimization and Notifications for Treatment and Outcomes (PRONTO)
Post-implementation of PRONTO-HN system: 1. Pre-operative risk stratification of requiring adjuvant therapy using our predictive model, applied at tumor board. Patients stratified as fast-track vs normal-track. 2. High-risk patients receive intensive preoperative and postoperative coordination. Low-risk patients are monitored but escalated rapidly if adverse pathology is detected. This includes: - pre-operative dental consultation for fast-track - pre-operative oncology consultation for fast-track with high-risk features - target pathology results 14 days post-operatively for fast-track 3. Automated reminders and target dates sent to members of the multidisciplinary team.
Surgery to post-operative radiotherapy time (S-PORT)
Number of days between surgery and start of radiotherapy (adjuvant)
Time frame: Day 1 of radiotherapy (assessed up to 12 weeks post-operatively)
Overall survival
Event: Death (of any cause) Censor: Alive at last follow-up
Time frame: From date of surgery until the date of date from any cause (assessed up to 60 months)
Locoregional Survival
Event: Locoregional recurrence (primary site or cervical node) or death Censored: Alive and without locoregional recurrence at last follow-up
Time frame: From date of surgery until the date of locoregional recurrence or death, whichever came first (assessed up to 60 months)
Distant metastasis-free survival
Event: Distant metastasis or death Censored: Alive and without distant metastasis at last follow-up
Time frame: The time from surgery to event. From date of surgery until the date of distant metastasis or death, whichever came first (assessed up to 60 months)
Recurrence-Free Survival
Event: Any recurrence (local, regional, or distant) Censored: Recurrence-free at last follow-up. Death without recurrence also censored.
Time frame: From date of surgery until the date of locoregional recurrence or distant metastasis, whichever came first (assessed up to 60 months)
Disease-Free Survival
Event: Recurrence (any site) or death Censored: Alive and disease-free at last follow-up
Time frame: From date of surgery until the date of locoregional recurrence or distant metastasis or death, whichever came first (assessed up to 60 months)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Oct 2026, 14 months after the start.
Of 98 non-industry interventional studies with no phase under Mouth Neoplasms, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 97. This study's planned 14 months is below that.
Counting every sponsor, half of 99 studies reached it within 30 months; a quarter within 17 and three quarters within 107.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre hospitalier de l'Université de Montréal (CHUM) →